The Trump administration's decision to link access to US health aid, including crucial support for HIV treatment, to the signing of new trade agreements with foreign governments has raised concerns among global health organizations and advocates. This policy shift has the potential to disrupt HIV care in countries with high prevalence rates, where millions of people are living with the virus.

According to sources familiar with the matter, the US government is urging countries to enter into new bilateral trade deals as a condition for receiving continued funding through programs that provide essential medicines and support services for individuals living with HIV. Critics argue that linking health aid to trade deals is an inappropriate and potentially harmful approach, as healthcare should be treated as a fundamental human right, not a bargaining chip in trade negotiations.

The administration's rationale behind this policy appears to be an effort to promote US trade interests and exert greater leverage in negotiations with foreign governments. However, experts warn that the policy could undermine decades of progress in combating HIV and other infectious diseases, and damage the United States' reputation as a reliable partner in global health. Disruption to aid programs could have devastating consequences, potentially leading to increased infections, preventable deaths, and setbacks in global efforts to control the epidemic.